Immunotherapy has been disappointing as treatment for prostate cancer, but a new Columbia trial suggests it has potential for treating metastatic disease.
After skin cancer, prostate cancer is the most common cancer diagnosed among men in the United States, and about one in eight men will be diagnosed with the disease during their lifetime.